Similar articles for PMID: 16094218

Year	Number of Results
1986	2
1994	1
1996	2
1997	2
1998	1
2002	3
2003	2
2004	2
2005	2
2006	12
2007	9
2008	11
2009	6
2010	4
2011	7
2012	10
2013	7
2014	12
2015	12
2016	5
2017	5
2018	10
2019	21
2020	17
2021	15
2022	12
2023	3
2024	2

1

Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.

Shinefield H, Black S, Williams WR, Marchant C, Reisinger K, Stewart T, Meissner HC, Guerrero J, Klopfer SO, Xu J, Schödel F, Kuter BJ; Dose Selection Study Group for Proquad. Shinefield H, et al. Pediatr Infect Dis J. 2005 Aug;24(8):670-5. doi: 10.1097/01.inf.0000172901.29621.e9. Pediatr Infect Dis J. 2005. PMID: 16094218 Clinical Trial.

2

Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.

Shinefield H, Black S, Digilio L, Reisinger K, Blatter M, Gress JO, Brown ML, Eves KA, Klopfer SO, Schödel F, Kuter BJ. Shinefield H, et al. Pediatr Infect Dis J. 2005 Aug;24(8):665-9. doi: 10.1097/01.inf.0000172902.25009.a1. Pediatr Infect Dis J. 2005. PMID: 16094217 Clinical Trial.

3

Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention (CDC). Marin M, et al. MMWR Recomm Rep. 2010 May 7;59(RR-3):1-12. MMWR Recomm Rep. 2010. PMID: 20448530 Free article.

4

A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.

Reisinger KS, Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, Matson DO, Silas PE, Schödel F, Gress JO, Kuter BJ; Protocol 014 Study Group for ProQuad. Reisinger KS, et al. Pediatrics. 2006 Feb;117(2):265-72. doi: 10.1542/peds.2005-0092. Pediatrics. 2006. PMID: 16452343 Clinical Trial.

5

The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.

Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ; Consistency Lot Study Group for ProQuad. Lieberman JM, et al. Pediatr Infect Dis J. 2006 Jul;25(7):615-22. doi: 10.1097/01.inf.0000220209.35074.0b. Pediatr Infect Dis J. 2006. PMID: 16804432 Clinical Trial.

6

Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, Prieler A, Maurer H, Bisanz H, Tornieporth N, Descamps D, Willems P. Knuf M, et al. Pediatr Infect Dis J. 2006 Jan;25(1):12-8. doi: 10.1097/01.inf.0000195626.35239.58. Pediatr Infect Dis J. 2006. PMID: 16395096

7

A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.

Marshall GS, Senders SD, Shepard J, Twiggs JD, Gardner J, Hille D, Hartzel J, Valenzuela R, Stek JE, Helmond FA. Marshall GS, et al. Hum Vaccin Immunother. 2016 Aug 2;12(8):2188-2196. doi: 10.1080/21645515.2016.1165374. Epub 2016 May 5. Hum Vaccin Immunother. 2016. PMID: 27149048 Free PMC article. Clinical Trial.

8

The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.

Durando P, Esposito S, Bona G, Cuccia M, Desole MG, Ferrera G, Gabutti G, Pellegrino A, Salvini F, Henry O, Povey M, Marchetti F. Durando P, et al. Vaccine. 2016 Aug 5;34(36):4278-84. doi: 10.1016/j.vaccine.2016.07.009. Epub 2016 Jul 14. Vaccine. 2016. PMID: 27423382 Free article. Clinical Trial.

9

Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.

Goh P, Lim FS, Han HH, Willems P. Goh P, et al. Infection. 2007 Oct;35(5):326-33. doi: 10.1007/s15010-007-6337-z. Epub 2007 Aug 20. Infection. 2007. PMID: 17710370 Clinical Trial.

10

Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.

Vesikari T, Baer M, Willems P. Vesikari T, et al. Pediatr Infect Dis J. 2007 Feb;26(2):153-8. doi: 10.1097/01.inf.0000250689.09396.21. Pediatr Infect Dis J. 2007. PMID: 17259879 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

175 results

Results by year